Edition:
United States

Bio Rad Laboratories Inc (BIOb.N)

BIOb.N on New York Stock Exchange

199.80USD
31 Mar 2017
Change (% chg)

-- (--)
Prev Close
$199.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
305
52-wk High
$203.20
52-wk Low
$137.95

BIOb.N

Chart for BIOb.N

About

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a... (more)

Overall

Beta: 0.90
Market Cap(Mil.): $6,240.55
Shares Outstanding(Mil.): 29.58
Dividend: --
Yield (%): --

Financials

  BIOb.N Industry Sector
P/E (TTM): 222.93 33.88 29.95
EPS (TTM): 0.95 -- --
ROI: 0.85 12.79 13.21
ROE: 1.11 14.87 14.38

Fitch Affirms Bio-Rad's IDR at 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) AUSTIN, April 05 (Fitch) Fitch Ratings has affirmed the ratings of Bio-Rad Laboratories, Inc. (Bio-Rad), including the 'BBB-' Issuer Default Rating (IDR). The ratings apply to approximately $437 million of debt at Dec. 31, 2016. The Rating Outlook is Stable. A full list of rating actions follows at the end of this release. KEY RATING DRIVERS Evolving Capital Allocation Strategy: Bio-Rad recently announced long-term targets for revenue g

Apr 05 2017

BRIEF-Bio Rad Laboratories management intends to three people for election to its board

* Management intends to propose Jeffrey Edwards, Gregory Hinckley and Arnold Pinkston for election to its board of directors

Mar 13 2017

BRIEF-Bio-Rad to acquire Raindance Technologies, Droplet Intellectual Property

* Bio-Rad to acquire Raindance Technologies and Droplet Intellectual Property

Jan 16 2017

BRIEF-Bio-Rad Q3 earnings per share $0.62

* Bio-Rad reports third-quarter currency-neutral revenue growth of 9.1 percent

Nov 01 2016

More From Around the Web

Earnings vs. Estimates